Firms Battle in Court Over Safety of Vaccine

BOSTON—The company that agreed to market the world's first genetically engineered pseudorabies livestock vaccine has charged the vaccine's developer with "fraudulent misrepresentation" of the vaccine's safety and efficacy. According to a claim filed November 13 in U.S. District Court in Houston, TechAmerica Group Inc. would not have entered into its agreement with Novagene Ltd. "had it known the truth with regard to such statements, representations and omissions" in the data presented on t

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

According to a claim filed November 13 in U.S. District Court in Houston, TechAmerica Group Inc. would not have entered into its agreement with Novagene Ltd. "had it known the truth with regard to such statements, representations and omissions" in the data presented on the product by Novagene in 1984.

TechAmerica's claims are a response to a suit brought against it October 31 by the Houston-based Novagene. Novagene has sued TechAmerica for breach of contract, claiming that the Elwood, Kan., company failed to advertise and market the product, even though the pseudorabies vaccine had been licensed by the U.S. Department of Agriculture (USDA) and made available for sale.

TechAmerica alleges that three key safety issues were initially misrepresented by Novagene: the vaccine's, capacity for reversion to virulence, its degree of safety for pregnant sows, and the extent to which the animals can shed the vaccine virus, potentially passing it into ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Seth Shulman

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide